Erratum to Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure (J Cachexia Sarcopenia Muscle, 10.1007/s13539-014-0155-9);Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure

Journal of Cachexia, Sarcopenia and Muscle

Volumn 5, Issue 4, 2014, Pages 297-305

  Khawaja, Tuba ^a   Chokshi, Aalap ^a   Ji, Ruiping ^a   Kato, Tomoko S ^a   Xu, Katherine ^a   Zizola, Cynthia ^a   Wu, Christina ^a   Forman, Daniel E ^a,b   Ota, Takeyoshi ^a   Kennel, Peter ^a   Takayama, Hiroo ^a   Naka, Yoshifumi ^a   George, Isaac ^a   Mancini, Donna ^a   Schulze, Christian P ^a  

^a Department of Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular surgery; Growth factors; Heart failure; Metabolism; Skeletal muscle

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CD36 ANTIGEN; GROWTH HORMONE; OLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DYNAMOMETRY; ENZYME LINKED IMMUNOSPOT ASSAY; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; GRIP STRENGTH; HAND GRIP; HEART FAILURE; HEART MUSCLE METABOLISM; HISTOLOGY; HUMAN; MALE; MEDICAL RECORD; MUSCLE CELL; REAL TIME POLYMERASE CHAIN REACTION; RECTUS ABDOMINIS MUSCLE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VENTRICULAR ASSIST DEVICE;

EID: 84951560723     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-014-0163-9     Document Type: Erratum

References (33)

1. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–34.
2. Schulze PC, Kratzsch J, Linke A, Schoene N, Adams V, Gielen S, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail. 2003;5(1):33–40.
3. Schulze PC, Biolo A, Gopal D, Shahzad K, Balog J, Fish M, et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail. 2011;17(12):1004–11.
4. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev. 2008;13(1):21–37.
5. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85(5):1751–9.
6. Habedank D, Meyer FJ, Hetzer R, Anker SD, Ewert R. Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure. J Cachex Sarcopenia Muscle. 2013;4(4):277–85.
7. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation. 2001;104(2):134–6.
8. Simonini A, Chang K, Yue P, Long CS, Massie BM. Expression of skeletal muscle sarcoplasmic reticulum calcium-ATPase is reduced in rats with postinfarction heart failure. Heart. 1999;81(3):303–7.
9. Duscha BD, Kraus WE, Keteyian SJ, Sullivan MJ, Green HJ, Schachat FH, et al. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. J Am Coll Cardiol. 1999;33(7):1956–63.
10. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9(6):366–76.
11. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38(2):443–52.
12. Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Yu J, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002;39(7):1175–81.
13. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005;115(2):451–8.
14. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351(9111):1233–7.
15. Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Erbs S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehab. 2005;12(4):401–6.
16. Lund LH, Freda P, Williams JJ, LaManca JJ, LeJemtel TH, Mancini DM. Growth hormone resistance in severe heart failure resolves after cardiac transplantation. Eur J Heart Fail. 2009;11(5):525–8.
17. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357(9):885–96.
18. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241–8.
19. Kato TS, Chokshi A, Singh P, Khawaja T, Cheema F, Akashi H, et al. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail. 2011;4(5):546–53.
20. Kato TS, Chokshi A, Singh P, Khawaja T, Iwata S, Homma S, et al. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure. J Heart Lung Transplant. 2012;31(1):37–45.
21. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail. 2012;5(3):340–8.
22. Mancini D, Goldsmith R, Levin H, Beniaminovitz A, Rose E, Catanese K, et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation. 1998;98(12):1178–83.
23. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation. 2012;125(23):2844–53.
24. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res. 2005;97(5):418–26.
25. Zierath JR, Hawley JA. Skeletal muscle fiber type: influence on contractile and metabolic properties. PLoS Biol. 2004;2(10):e348.
26. Niebauer J, Pflaum CD, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. JACC. 1998;32(2):393–7.
27. Lenk K, Palus S, Schur R, Datta R, Dong J, Culler MD, et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachex Sarcopenia Muscle. 2013;4(1):63–9.
28. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004;14(3):395–403.
29. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3(11):1014–9.
30. Raymond AL, Kfoury AG, Bishop CJ, Davis ES, Goebel KM, Stoker S, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56(1):57–60.
31. Emani S, Brewer RJ, John R, Slaughter MS, et al. Patients with low compared with high body mass index gain more weight after implantation of a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2013;32:31–5.
32. Tadaishi M, Miura S, Kai Y, Kano Y, Oishi Y, Ezaki O. Skeletal muscle-specific expression of PGC-1alpha-b, an exercise-responsive isoform, increases exercise capacity and peak oxygen uptake. PLoS One. 2011;6(12):e28290.
33. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia, and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.